Appendix D 
NON-TECHNICAL ABSTRACT : 
Autologous bone marrow transplantation is a technique which 
makes safe the very high doses of chemotherapy and radiation which 
are required to eradicate some populations of leukemia cells. The 
marrow is stored from the hip bone of the patient at the time of 
remission induced by conventional dose chemotherapy, and re-infused 
into the patient after intensive therapy in order to restore marrow 
function. It is impossible to determine if relapse arises from 
residual leukemia cells infused with the autologous marrow or if 
residual leukemia cells present in systemic circulation after 
intensive therapy contribute to the relapse. A molecule called a 
"marking vector" can be used to resolve this question. A portion 
of the bone marrow and peripheral blood cells stored from patients 
will be incubated with the marking vector. This vector will 
introduce a new marker into these leukemia cells. If the leukemia 
cells appearing at relapse contain the marker, then the relapse 
arose from cells infused with the autologous transplantation. If 
this is the case, more thorough procedures must be undertaken to 
cleanse the marrow of leukemia cells. If no markers appear at the 
time of relapse in the leukemia cells, then the relapse arose from 
the systemic circulation. In this case, the therapy used to 
eradicate leukemia from the circulation before transplant must be 
intensified. In this study, a marking molecule, called LNL6, will 
be used to tag the leukemic blast cells of each patient infused to 
regenerate marrow function after intensive therapy. The results of 
this study will be used to improve the results of therapy. 
[770] 
Recombinant DNA Research, Volume 14 
